Patents by Inventor Jerry Andrew Taylor
Jerry Andrew Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11008313Abstract: The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.Type: GrantFiled: September 15, 2017Date of Patent: May 18, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
-
Publication number: 20200369657Abstract: The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.Type: ApplicationFiled: September 15, 2017Publication date: November 26, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
-
Patent number: 9567333Abstract: This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: October 19, 2015Date of Patent: February 14, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Paul Ratcliffe, Jerry Andrew Taylor, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Patent number: 9522141Abstract: This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: December 17, 2013Date of Patent: December 20, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Scott B. Hoyt, Jerry Andrew Taylor, Clare London, Yusheng Xiong, Andrew John Cooke
-
Patent number: 9518055Abstract: This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: October 16, 2015Date of Patent: December 13, 2016Assignee: Merck Sharp & DohmeInventors: Amjad Ali, D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Michael Lo, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Jerry Andrew Taylor, Brent Whitehead, Yusheng Xiong
-
Publication number: 20160039817Abstract: This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: October 19, 2015Publication date: February 11, 2016Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Paul Ratcliffe, Jerry Andrew Taylor, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20160031882Abstract: This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: October 16, 2015Publication date: February 4, 2016Inventors: Amjad Ali, D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Michael Lo, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Jerry Andrew Taylor, Brent Whitehead, Yusheng Xiong
-
Patent number: 9193724Abstract: This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: September 17, 2012Date of Patent: November 24, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Paul Ratcliffe, Jerry Andrew Taylor, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20150320733Abstract: This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: December 17, 2013Publication date: November 12, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Scott B. Hoyt, Jerry Andrew Taylor, Clare London, Yusheng Xiong, Andrew John Cooke
-
Patent number: 9173873Abstract: This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: September 17, 2012Date of Patent: November 3, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Michael Lo, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Jerry Andrew Taylor, Brent Whitehead, Yusheng Xiong
-
Patent number: 9073929Abstract: This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: GrantFiled: April 20, 2012Date of Patent: July 7, 2015Assignees: ElexoPharm GmbH, Merck Sharp & Dohme Corp.Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20140235667Abstract: This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: September 17, 2012Publication date: August 21, 2014Inventors: Amjad Ali, D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Michael Lo, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Jerry Andrew Taylor, Brent Whitehead, Yusheng Xiong
-
Publication number: 20140228396Abstract: This invention relates to triazolopyridyl compounds of the structural formula: [Formula should be inserted here] or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: September 17, 2012Publication date: August 14, 2014Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Paul Ratcliffe, Jerry Andrew Taylor, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20140045819Abstract: This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: ApplicationFiled: April 20, 2012Publication date: February 13, 2014Applicants: ElexoPharm GmbH, SCHERING CORPORATIONInventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni